Thoratec upgraded to Buy from Neutral at Goldman

October 14, 2013

Goldman upgraded Thoratec due to an improved competitive position from recent reimbursement policy decisions, geographic expansion, new product launches and delays at competitor HeartWare. Price target raised to $46 from $40.